Quanterix Corporation · NASDAQ:QTRX

Quanterix — Q4 2023 Earnings Presentation

16 slides from Quanterix's earnings presentation, Feb 29, 2024

  1. Slide 1: Fourth Quarter 2023 Earnings

    „ Fourth Quarter 2023 Earnings February 29, 2024

  2. Slide 2: Forward-Looking Statements & Non-GAAP Financial Measures

    Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (a

  3. Slide 3: Corporate Transformation: Assay Redevelopment Roadmap

    Corporate Transformation: Assay Redevelopment Roadmap Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023  CEO transition  Strategic review  Stability and  Manufacturing  Manufacturing  Continued bridging  Optimized on April 25th completed in July, variance implementation implemen

  4. Slide 4: Strong foundation for a ramping innovation rate in 2024

    Strong foundation for a ramping innovation rate in 2024 Launched 0 Launched ≥20 assays a year new assays 5 new assays Develop platform One LDT Test One LDT Test (Plexity & automation) IVD launch Harmonized processes driving rapid menu expansion Assay development times reduced from >18 months to <6 m

  5. Slide 5: Delivering an efficient operating framework

    Delivering an efficient operating framework Improvement of 50% Improvement of 300% Increase of 80% in 6 quarters in 6 quarters in 6 quarters Testing Scale Manufacturability Studies with capacity to with capacity to supported in increase to 3x increase to 3x Neurology Accelerator Assay Research Lab M

  6. Slide 6: Alzheimer's Diagnostic Opportunity

    Alzheimer’s Diagnostic Opportunity Allocating capital to execute commercial adoption Reimbursement: Submitted for CPT code (expected in 2024) Over $20M of capital 1 FDA: allocated for next 2 years to Breakthrough designation received for 2 ‘ (expecting 3rd in 2024) advance AD Diagnostics Updates on

  7. Slide 7: Building the Testing Infrastructure for Alzheimer's Disease

    Building the Testing Infrastructure for Alzheimer's Disease These health systems represent:  140+ hospitals  Across 18 states  Caring for approximately 21 million patients 7

  8. Slide 8: Unique power of ultra-sensitivity

    LucentAD p-Tau 217 is just the start… Tomorrow Unique power of ultra-sensitivity Today …uniquely set to lead the decade of Neuro Access Menu Workflow Affordability CSF and Blood-based markers >950 Installed Differential Low cost DBS base Diagnosis (in development) (in development) 8

  9. Slide 9: Scientific Validation Driving Adoption

    Scientific Validation Driving Adoption Neurology Immunology & Oncology Infectious Diseases Others INSTRUMENTS PUBLICATIONS BIOMARKERS Placements Cumulative Cumulative # of units placed Cumulative 27.8 223 2,781 559 972 538 Number of Drug Trial Projects 23.7 876 168 480 149 2,141 132 403 708 18.0 101

  10. Slide 10: Q4FY23 Results vs PYQ4

    Q4FY23 Results vs PYQ4 (in $ millions) Q4 GAAP Q4 Non-GAAP 2022 2023 2022 2023 INSTRUMENTS CONSUM ABLES ACCELERATOR STRATEGIC COLLABORATIONS OTHER Revenue 25.8 31.5 25.8 31.5 Revenue Mix 10% 56% 18% 5% 12% Gross Margin $ 12.6 16.8 10.7 14.7 Gross Margin % 48.8% 53.2% 41.3% 46.5% GAAP Revenue Q4 2022

  11. Slide 11: FY23 Results vs FY22

    FY23 Results vs FY22 (in $ millions) FY GAAP FY Non-GAAP 2022 2023 2022 2023 INSTRUMENTS CONSUM ABLES ACCELERATOR STRATEGIC COLLABORATIONS OTHER Revenue 105.5 122.4 105.5 122.4 Revenue Mix 13% 52% 18% 5% 12% Gross Margin $ 46.8 70.6 39.6 62.5 Gross Margin % 44.4% 57.7% 37.5% 51.1% GAAP Revenue FY 20

  12. Slide 12: Strong Balance Sheet

    Strong Balance Sheet Cash Liquidity1 Burn 2023 Reduced cash burn from operations $324M $17M Well positioned to fund strategic priorities to enable organic growth Stable Reduced Provides optionality for future opportunities 2022 $341M $58M 1 Includes Cash, Cash Equivalents, Marketable Securities, and

  13. Slide 13: 2024 Guidance

    2024 Guidance Full Year Revenue FY 2024 Revenue expected to be between $139 to $144 million. Annual revenue guidance excludes Diagnostics. Gross Margin Estimated FY 2024 GAAP Gross Margin percentage to be 57-61% and Non-GAAP Gross Margin percentage to be 51-55%. Cash Usage • 2024 full year cash usag

  14. Slide 14: Reconciliation of GAAP to Non-GAAP Financial Measures (1 of 2)

    Reconciliation of GAAP to Non-GAAP Financial Measures (1 of 2) Quanterix Corporation Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited and in thousands, except percentages) Thre e Months Ende d De ce mbe r 31, Ye ar Ende d De ce mbe r 31, 2023 2022 2023 2022 GAAP gr

  15. Slide 15: Reconciliation of GAAP to Non-GAAP Financial Measures (2 of 2)

    Reconciliation of GAAP to Non-GAAP Financial Measures (2 of 2) Quanterix Corporation Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited and in thousands, except percentages) Thre e Months Ende d, Twe lve Months Ende d, June 2022 Se pte mbe r 2022 De ce mbe r 2022 Mar

  16. Slide 16: „

    „

Quanterix — Q4 2023 Earnings Presentation on 6ix